SIREN : 878403120
SPFPL PHARMAKIS is a French company founded 6 years ago, specialized in the sector Activités des sociétés holding. Based in BARRAUTE-CAMU (64390), this company of category PME shows in 2021 a revenue of 120 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2021 | 2020 |
|---|---|---|
| Revenue | 120 000 € | N/C |
| Net income | 229 443 € | -11 001 € |
| EBITDA | 21 626 € | -2 310 € |
| Net margin | 191.2% | N/C |
In 2021, SPFPL PHARMAKIS achieves revenue of 120 k€. After deducting consumption (0 €), gross margin stands at 120 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 22 k€, representing 18.0% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 229 k€, i.e. 191.2% of revenue. This profit can be retained or distributed to shareholders.
120 000 €
120 000 €
21 626 €
21 626 €
229 443 €
18.0%
The debt ratio (= Financial debt / Equity x 100) stands at 62%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 62%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 1.9 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 191.2% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
61.876%
61.565%
191.202%
1.873
In 2021, the debt ratio of SPFPL PHARMAKIS (61.88) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2021, the financial autonomy of SPFPL PHARMAKIS (61.6%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2021, the repayment capacity of SPFPL PHARMAKIS (1.87) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 3390.78. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 36.8x. Operating income very largely covers interest expenses: high safety margin.
3390.779
36.803
In 2021, the liquidity ratio of SPFPL PHARMAKIS (3390.78) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2021, the interest coverage of SPFPL PHARMAKIS (36.8x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 298 days. Excellent situation: suppliers finance 298 days of the operating cycle (retail model). Overall, WCR represents 96 days of revenue, i.e. 32 k€ to permanently finance.
32 083 €
0 j
298 j
0 j
96 j
Based on 98 transactions of similar company sales
in 2021,
the value of SPFPL PHARMAKIS is estimated at
293 388 €
(range 112 524€ - 744 189€).
With an EBITDA of 21 626€, the sector multiple of 5.2x is applied.
The price/revenue ratio is 0.46x
(conservative valuation).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 98 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare SPFPL PHARMAKIS with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of SPFPL PHARMAKIS in 2021 is 120 k€.
Yes, SPFPL PHARMAKIS generated a net profit of 229 k€ in 2021.
The headquarters of SPFPL PHARMAKIS is located in BARRAUTE-CAMU (64390), in the department Pyrenees-Atlantiques.
The tax return of SPFPL PHARMAKIS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
SPFPL PHARMAKIS operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.